Flurbiprofen axetil 

Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway^{[1][2][3][4][5]}.

Flurbiprofen axetil (0-160 nM, 1-6 days) does not affect the proliferation and activity, but inhibits migration and invasion in BT-549 and MDA-MB-231 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Flurbiprofen axetil (0.1 g/100 mL, drops into the eyes, 2 times/day, 24 h) has anti-inflammation effect in endotoxin-induced uveitis (EIU) rabbit model^[1].
Flurbiprofen axetil (10  mg/kg, i.p., once every two days, 28 days) inhibits breast cancer metastasis via inhibiting MEK/ERK signaling pathway in nude mice model^[2].
Flurbiprofen axetil (10 mg/kg, i.v., once) could promote a neuroprotective effect by, or in part, activation of PPAR-γ after focal cerebral ischemia in rat^[3].
Flurbiprofen axetil (5-10 mg/kg, i.v., once) protects the brain from cerebral I/R injury through reducing inflammation and brain edema in global cerebral ischemia male SD rat^[4].
Flurbiprofen axetil (10 mg/kg, i.v., once) can reduce the inflammatory response and cognitive function through the AMPKα/NF-κB signaling pathway.in formalin-induced MCI SD rat model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

330.35

C₁₉H₁₉FO₄

91503-79-6

Oil

Colorless to off-white

O=C(OC(OC(C)=O)C)C(C)C1=CC=C(C2=CC=CC=C2)C(F)=C1

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Shen J, et al. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int J Pharm. 2011 Jun 30;412(1-2):115-22.  [Content Brief]

  [2]. Zhu Y, et al. Flurbiprofen axetil is involved in basal-like breast cancer metastasis via suppressing the MEK/ERK signaling pathway. Cell Biol Int. 2025 Jan;49(1):68-78.  [Content Brief]

  [3]. Liu JL, et al. Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats. Chin Med J (Engl). 2012 Oct;125(20):3719-24.  [Content Brief]

  [4]. Wu H, et al. Flurbiprofen axetil attenuates cerebral ischemia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion. Biosci Rep. 2018 Jul 6;38(4):BSR20171562.  [Content Brief]

  [5]. Huang L, et al. Flurbiprofen axetil alleviates the effect of formalin-induced inflammatory pain on the cognitive function of rats with mild cognitive impairment through the AMPKα/NF-κB signaling pathway. Ann Transl Med. 2022 Nov;10(22):1210.  [Content Brief]